TEVA Q2 2024 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.2B+7.4% YoY

Gross Profit

$2.0B48.6% margin

Operating Income

-$5M-0.1% margin

Net Income

-$846M-20.3% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

+9.0%

Cash Flow

Operating Cash Flow

$103M

Free Cash Flow

$6M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$41.3B

Total Liabilities

$34.8B

Stockholders' Equity

$6.4B

Cash & Equivalents

$2.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.2B	$3.9B	+7.4%
Gross Profit	$2.0B	$1.8B	+12.7%
Operating Income	-$5M	-$654M	+99.2%
Net Income	-$846M	-$872M	+3.0%

Revenue Segments

Product

$3.6B87%

Distribution Service

$382M9%

Product and Service, Other

$106M3%

License

$36M1%

Geographic Segments

North America Segment

$2.1B54%

Europe Segment

$1.2B31%

International Markets

$593M15%